16 results about "Ophthalmic use" patented technology

Provided herein are biopolymers comprising repeating polysaccharide units, preparations of biopolymers, and ophthalmic compositions comprising biopolymers, as well as methods of use.

A method for stabilizing a composition for ophthalmic use containing sepetaprost is disclosed. More specifically, a method that facilitates retention of sepetaprost stability at high temperatures, and further, a method that facilitates the retention of preservative effectiveness of the composition for ophthalmic use are disclosed. The composition for ophthalmic use contains sepetaprost at a concentration of 0.0001 to 0.003% (w / v) and has a pH within a range from 5 to 8.

The purpose of the present invention is to discover a method for stabilizing a composition for ophthalmic use containing sepetaprost, more specifically, a method that facilitates retention of sepetaprost stability at high temperatures, and further, a method that facilitates the retention of preservative effectiveness of this composition for ophthalmic use. The present invention is a composition for ophthalmic use, which contains sepetaprost at a concentration of 0.0001 to 0.003% (w / v) and has a pH within a range from 5 to 8.

The present invention relates to a method for alleviating asthenopia and a liquid composition for ophthalmic use. Specifically, on one hand, the invention relates to a liquid composition for eyes. The invention relates to a skin-care lotion, which is prepared from the following components: glycerol, p-hydroxyacetophenone, sodium hyaluronate, propylene glycol, menthol, borneol, methyl diisopropyl propionamide, menthol, SOLUBILISANT LRI, edetate disodium, water-locking magnetite, radix gentianae extract, totarol, sodium citrate, ectodoine, ergothioneine, hydrolyzed red algae extract and water. Furthermore, the invention also relates to an application of the liquid composition in preparation of a product for relieving eye asthenopia for eye use. The liquid composition of the present invention exhibits excellent properties, for example as described in the specification.

The present invention relates to a novel pharmaceutical composition suitable for ophthalmic use comprising antibiotic and process to prepare the same. More particularly, the present invention relates to a pharmaceutical gel composition comprising aminoglycoside antibiotics such as plazomicin or its pharmaceutically acceptable salts thereof for the treatment of ocular infections.

The utility model discloses a medical atomization eyeshade for the ophthalmology department, and relates to the technical field of atomization eyeshades. The eyeshade comprises two eyeshade bodies, connecting rings are fixedly connected to the opposite sides of the eyeshade bodies, annular grooves are formed in the side faces of the connecting rings, two protrusions distributed in a central symmetry mode are fixedly connected to the sides, close to each other, of the connecting rings, and a three-way pipe is arranged between the two eyeshade bodies. Appropriate rotation starting torque is applied to the three-way pipe, due to the soft property of plastic materials, the protrusions are disengaged from the interiors of the grooves, the annular sliding rails are driven to slide along the inner sides of the annular grooves, and when the three-way pipe vertically rotates by 90 degrees, the protrusions correspond to the other grooves in position and are clamped into the grooves again, so that the three-way pipe is prevented from rotating. And the three-way pipe is reversely rotated, in the same way, the three-way pipe is reset, and the flexibility of the equipment is further improved.

The present invention relates to an eye drop composition comprising imatinib. The present invention relates to an eye drop composition and a method for preparing same, in which the eye drop composition is prepared at a pH level suitable as an eye drop while an appropriate amount of an imatinib derivative is dissolved even within a relatively high pH range, compared to conventional compositions prepared under pH conditions (< pH 5.5) unsuitable for eye drop, in order to dissolve imatinib, and has improved phase stability, long-term stability, bioavailability, and eye irritation.

The present invention relates to novel pharmaceutical compositions containing antibiotics, such as plazomycin or a pharmaceutically acceptable salt thereof, suitable for ophthalmic use for use in the treatment of eye infections, and methods for their preparation.

Methods, devices, and systems for use in integrating an electronic device in an ophthalmic article to produce, e.g., electronic eyewear such as electrochromic eyewear, that reduces susceptibility to structural damage during thermal forming, that is scalable for mass manufacturing, and that exhibits the requisite conductivity, sheet resistance, and optical transparency for ophthalmic uses.

A gel formulation for topical ophthalmic use, the gel formulation comprising a compound of formula (I).

A pharmaceutical composition is disclosed comprising an insulin, a set of excipients, and a penetration enhancer, wherein the penetration enhancer is a prostaglandin analogue configured to enhance the permeability of insulin upon topical ocular administration. The composition enables increased transport of insulin across ocular tissues, improving absorption and bioavailability following topical delivery to the eye. The formulation includes pharmaceutically acceptable excipients such as surfactants, buffering agents, viscosity enhancers, tonicity agents, preservatives, and solvents suitable for ophthalmic use. The invention provides a non-invasive route of administering insulin through the eye, allowing systemic or local therapeutic effects without injection.

The present invention relates to novel pharmaceutical compositions suitable for ophthalmic use comprising an antibiotic, such as prazomicin or a pharmaceutically acceptable salt thereof, as well as a process for the preparation thereof for the treatment of ocular infections.

Implantable or wearable lens for ophthalmic use, having a front surface and a rear surface, wherein at least one surface of said front surface and rear surface has a refractive profile of the multi-zone aspheric type with circular or rotational symmetry, with respect to the optical axis, and having a geometric elevation z(r) defined by a Forbes polynomial series expansion. This refractive profile enhances the wavefront W(r) emerging from the lens, progressively and continuously extending the depth of field in a range of powers preferably comprised between -1,0D and 4.0D; and improves the quality of vision in Far Field for pupil diameters greater than a value ϕ. Furthermore, the rear surface of the lens can include a toric-type profile adapted to correct residual corneal astigmatism.

The utility model belongs to the technical field of medical supplies, and particularly relates to a surgical towel for the ophthalmology department. The utility model provides an ophthalmologic operation towel which is used for accurately measuring and positioning the axial position of an astigmatism crystal in a non-contact mode in the ophthalmologic operation process. The operation towel comprises a main body of the operation towel, transparent stickers corresponding to eyes are arranged on the main body, and the operation towel is characterized in that a transverse rod is arranged on the outer surface of the main body and located on one side of the transparent stickers, the transverse rod corresponds to a human eyebrow bone, and a vertical line mark corresponding to a human nasal bone is further arranged on the outer surface of the main body; a transverse shaft is arranged on the side, opposite to the transverse rod, of the transparent paste on the outer surface of the body, a transparent film corresponding to the transparent paste sleeves the transverse shaft in a movable and turnover mode, and a positioning mark line is arranged on the transparent film.

The present invention relates to the field of biotechnology and medicine. The invention consists of a formulation for topical ophthalmic use that contains Helenalin, 11-α, 13-dihydrohelenalin and flavonoids from Arnica Montana extract in combination with sodium hyaluronate for the primary treatment and / or as an adjuvant of dry eye syndrome in humans. Dry eye syndrome is one of the most commonly observed clinical conditions worldwide with an estimated population occurrence of 9 - 30%. In addition, Dry Eye Syndrome has very pertinent inflammatory and oxidative aspects which require diverse strategies to help in its treatment. The availability of a formulation which has anti-inflammatory and antioxidant properties in addition to a lubricating function is of great interest to the scientific and medical community.

A pharmaceutical composition for an ophthalmic use either in humans or mammalians for a treatment of eye disorders is provided. The pharmaceutical composition includes an effective amount of an oxidizing agent and an effective amount of a photo-sensitizing agent, in combination with pharmaceutically acceptable excipients; the photo-sensitizing agent is a molecule having an absorbance peak in a wavelength range between 340 nm and 440 nm and emits fluorescence in a wavelength range between 450 nm and 600 nm; the oxidizing agent is chosen among molecules, wherein the molecules partially or totally inhibit a mitochondrial electron transport chain activity, wherein the pharmaceutical composition is a liquid formulation further includes one or more substances chosen among: diluents, permeabilizers, disinfectants, buffer systems, salts, antiseptics, and the pharmaceutically acceptable excipients.